(IN BRIEF) Boehringer Ingelheim and the WHO Foundation have partnered to promote equitable healthcare access and suicide prevention, with a focus on vulnerable communities in the Americas. Boehringer Ingelheim pledged $5 million to support WHO’s 2025–2028 General Program of Work … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Society
Tagged Anil Soni, Boehringer Ingelheim, Global Healthcare Access, Médard Schoenmaeckers, mental health, partnership, society, Suicide Prevention Efforts, WHO Foundation
(IN BRIEF) Boehringer Ingelheim and CDR-Life have reported positive results from the Phase I trial of BI 771716, an investigational treatment for geographic atrophy (GA), a severe form of age-related macular degeneration. The antibody fragment met its primary safety endpoints, … Read the full press release
(IN BRIEF) In a significant stride towards combating metabolic dysfunction-associated steatohepatitis (MASH), Boehringer Ingelheim unveils groundbreaking results from a Phase II trial sub-analysis of survodutide. Demonstrating impressive efficacy, up to 64.5% of adults with moderate to advanced fibrosis stages F2 … Read the full press release
(IN BRIEF) A recent study commissioned by Boehringer Ingelheim, conducted across eight G20 countries, sheds light on the challenges obstructing access to mental health care worldwide. The analysis reveals pervasive stigma, a shortage of mental health professionals, and inconsistent service … Read the full press release
(IN BRIEF) Boehringer Ingelheim and OSE Immunotherapeutics announce a significant expansion of their partnership, introducing two novel projects to develop pioneering treatments alongside their ongoing anti-SIRPα immuno-oncology initiatives. The expansion includes broadening therapeutic evaluations to encompass cardiovascular-renal-metabolic (CRM) diseases and … Read the full press release
Posted in Business, Education, Environment, Financial, France, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Boehringer Ingelheim, Clive R. Wood, Disease Treatment, Nicolas Poirier, OSE Immunotherapeutics, partnership, sustainability
(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged 8th annual Patients as Partners® Europe, AbbVie, Anders Lassen, Andrew Garvey, Annie Gilbert, Astellas, AstraZeneca, Biotech, Boehringer Ingelheim, clinical operations, clinical research, clinical trials, Conference, David James, decentralized clinical trials, Derek Stewart, diversifying clinical trials, diversity, drug development, England, GSK, Health Equity, inclusivity, inclusivity in clinical research, Ipsen, LGBTQ+ oncology, Lisa Kerr, London, Lundbeck, Novartis, Novo Nordisk, Oleksandr Gorbenko, Parexel, Patient Advocacy, patient engagment, patient experience mapping, Patrick Gallogly, Pfizer, pharma, Plaisterers’ Hall, Prostate Cancer Research, Rosamund Round, Sanofi, Sarah Zenner Dolan, Stephen Head, The Conference Forum, Valerie Bowling, Victoria DiBiaso, , Alfred Samuel
(IN BRIEF) Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have unveiled a global collaboration and exclusive option-to-license agreement aimed at advancing the development and commercialization of Sosei Heptares’ portfolio of first-in-class GPR52 agonists. The focus of this collaboration lies … Read the full press release
Posted in Business, Education, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Boehringer Ingelheim, GPR52 agonists, Hugh Marston, Matt Barnes, mental health, partnership, schizophrenia, Sosei Heptares, sustainability, treatment
(IN BRIEF) Boehringer Ingelheim has reported compelling results from its Phase II trial of Survodutide, a novel glucagon/GLP-1 receptor dual agonist, indicating its potential to become a leading treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). In the trial, up to 83.0% … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Boehringer Ingelheim, Carinne Brouillon, Dr. Arun Sanyal, MASH, Phase II Trial, Survodutide, treatment
(IN BRIEF) Boehringer Ingelheim has been honored by the Top Employers Institute with a “Global Top Employer” certification for the fourth consecutive year, distinguishing it as one of only 17 globally certified companies. The recognition is attributed to the company’s … Read the full press release
Posted in Awards, Business, Germany, Industrial, Management, News, Pharma & Biotech
Tagged Awards, Boehringer Ingelheim, Employee Development, Global Top Employer, Sven Sommerlatte, wellbeing
(IN BRIEF) Boehringer Ingelheim and IBM have formed a partnership to expedite the discovery of novel candidate antibodies for therapeutic purposes. Boehringer will utilize IBM’s foundation model technologies, combining them with their proprietary data to enhance the antibody discovery process. … Read the full press release
(IN BRIEF) Pharmaceutical company Boehringer Ingelheim has declared its intention to move forward with survodutide, a dual agonist targeting the glucagon/GLP-1 receptors, into three Phase III clinical trials for individuals suffering from overweight or obesity. This decision stems from promising … Read the full press release
(IN BRIEF) Boehringer Ingelheim has begun construction on a new Chemical Innovation Plant at its headquarters in Ingelheim, Germany. The €285 million investment will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for clinical trial phases, enabling Boehringer … Read the full press release
(IN BRIEF) The Conference Forum has announced that the 7th annual European Patients as Partners® in Clinical Research conference will take place in London on June 12-13, 2023. The event will focus on achieving greater representation in clinical research, building … Read the full press release
Posted in Government, Healthcare, News, Non Profit, Pharma & Biotech, United Kingdom
Tagged 7th annual European Patients as Partners®, biotechnology, Boehringer Ingelheim, Center for BME Health, clinical development, clinical research, Clinical Research conference, clinical trials, Community Engagement, CSL Behring, Deirdre BeVard, Diversity in Clinical Research, drug development, government, Health Equity, Healthcare, Hospital, Lundbeck, Medicine Development, Medicine Lifestyle, Medicines Development, Novartis, Patient Advocacy, Patient Centricity, Patient Communities, patient engagement, Patient Perspective, Patient Recruitment, Patient Retention, Patient Voice, Patients as Partners, Pharmaceutical, research and development, Sanofi, The Conference Forum, Thistle Hotel Marble Arch, Valerie Bowling
(PRESS RELEASE) INGELHEIM, 17-Jan-2023 — /EuropaWire/ — Boehringer Ingelheim, one of the world’s leading research-driven pharmaceutical companies with 130 years of experience, has announced it has been named a “Global Top Employer” for the third year in a row by the … Read the full press release
Posted in Awards, Germany, Healthcare, Management, Pharma & Biotech
Tagged Boehringer Ingelheim, Corporate World, counselors, Dr Sven Sommerlatte, employee healthcare, Employee Wellbeing, Global Top Employer, mental health, outstanding employer benefits, pharmaceutical company, positive work environment, prestigious honor, psychologists, Top Employers Institute, wellbeing, work life balance
(COMUNICADO DE PRENSA) INGELHEIM, 17-Jan-2023 — /EuropaWire/ — Boehringer Ingelheim, una de las principales compañías farmacéuticas del mundo impulsadas por la investigación con 130 años de experiencia, ha anunciado que ha sido nombrada “Global Top Employer” por tercer año consecutivo por … Read the full press release
Posted in Awards, Germany, Healthcare, Management, Pharma & Biotech
Tagged ambiente de trabajo positivo, atención médica para empleados, beneficios sobresalientes para empleadores, bienestar, Bienestar de los empleados, Boehringer Ingelheim, compañía farmacéutica, consejeros, Corporate World, Dr. Sven Sommerlatte, equilibrio entre la vida personal y laboral, Global Top Employer, honor prestigioso, psicólogos, salud mental, Top Employers Institute
Metacam® 0.5mg/ml Oral Suspension for Cats is now also approved in Europe for alleviation of mild to moderate post-operative pain associated with soft tissue surgery in guinea-pigs True market need to provide relief after painful procedures and surgeries Boehringer Ingelheim is … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged analgesic, anti-inflammatory, Boehringer Ingelheim, Europe, guinea pigs, medicine, Metacam®, Shawn Hooker, Veterinary Medicines
The programme was set up by the International Society of Feline Medicine (ISFM), the veterinary division of the charity International Cat Care (ICC) Boehringer Ingelheim will promote the programme and develop informational tools and services to grow veterinarians’ and cat … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Tagged Boehringer Ingelheim, Cat Friendly Clinic programme, Shawn Hooker
61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1 Survey underlines the importance of appropriate support and coping mechanisms for patients living with IPF1 Healthcare teams emphasise the need of a strong support network … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Society
Tagged Boehringer Ingelheim, Dr. Marlies Wijsenbeek, idiopathic pulmonary fibrosis, IPF, survey
New start-up as platform for digital transformation in data science, agile software development and user experience design Improvement of human and animal health with innovative digital solutions BI X offers 50 new jobs at the company’s headquarters Investment of 10 … Read the full press release
Both companies will become global leaders in two different sectors of the pharmaceutical market Paris (France) and Ingelheim (Germany), 03-Jan-2017 — /EuropaWire/ — Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an … Read the full press release
360 million people worldwide suffer from disabling hearing loss with no effective treatment available New collaboration with China Southeast University is part of the Research Beyond Borders (RBB) initiative, which aims to explore emerging science within and beyond Boehringer Ingelheim’s … Read the full press release
After 12 weeks, approximately twice as many patients with moderate-to-severe Crohn’s disease, the majority of whom had previously failed treatment with one or more TNF antagonists, achieved clinical remission with risankizumab compared with placebo1 Endoscopic remission was achieved in 15% … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged Boehringer Ingelheim, Dr. Brian G. Feagan MD, Risankizumab
• Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases.1,2 • Approval of Giotrif® is based on results of the LUX-Lung 8 study, … Read the full press release
Posted in European Union, Germany, Healthcare, Pharma & Biotech, Science
Tagged anticoagulant, Boehringer Ingelheim, dabigatran, Dr. Mehdi Shahidi, idarucizumab
• Results of global Phase IIb LUX-Lung 7 trial demonstrate afatinib superior in reducing the risk of lung cancer progression and the risk of treatment failure both by 27% compared to gefitinib1 • More patients on afatinib were free of … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech
Ingelheim, 20-11-2015 — /EuropaWire/ — Boehringer Ingelheim has been named one of the most innovative companies worldwide in 2015. For the first time, the research-driven pharmaceutical company ranked among the 100 leading global innovators named by news agency Thomson Reuters. Thomson … Read the full press release
Posted in Awards, Germany, Healthcare, Media
Tagged 100 leading global innovators by Thomson Reuters, Boehringer Ingelheim
Your Time campaign calls for earlier action in COPD WHO expects COPD to be the third leading cause of death worldwide by 2030 – exceeded only by heart disease and stroke1 By the time most people know they have COPD, … Read the full press release
Posted in Germany, Healthcare, Society
Tagged Boehringer Ingelheim, Chronic obstructive pulmonary disease, COPD, Dr. Richard Russell
OTEMTO® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto® Respimat® right from the initial stage when patients first need maintenance therapy* Head-to-head ENERGITO® study shows superior lung function improvements with Spiolto® Respimat® versus LABA/ICS FDC AMSTERDAM, 29-9-2015 … Read the full press release
Posted in Germany, Healthcare, Netherlands, Pharma & Biotech
Tagged Boehringer Ingelheim, COPD, Spiolto® Respimat®
Not for audiences in the US and Canada LONDON, 26-8-2015 — /EuropaWire/ — This week, epgonline.org, the website for healthcare professionals, welcomes the launch of a free symptomatic asthma Continuing Medical Education (CME) activity, available at epgonline.org/symptomatic-asthma/cme/. Accredited by the … Read the full press release
Ingelheim, Germany and Indianapolis, US, 24-8-2015 — /EuropaWire/ — Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 … Read the full press release
Initial combinations of empagliflozin and metformin in patients with T2D led to significant reductions in blood glucose vs. empagliflozin or metformin alone at 24 weeks Ingelheim, Germany and Indianapolis, US, 8-6-2015 — /EuropaWire/ — A Phase III clinical trial has … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged blood glucose, Boehringer Ingelheim, empagliflozin, metformin, Professor Hans-J. Woerle, type 2 diabetes
In patients with no prior maintenance treatment, tiotropium/olodaterol Respimat® more than doubled the improvement in lung function* compared to Spiriva® Respimat® alone1 Tiotropium/olodaterol Respimat® showed efficacy across all COPD stages with greatest lung function improvements over Spiriva® Respimat® in early … Read the full press release
CAMBRIDGE, Massachusetts and INGELHEIM, Germany, 14-4-2015 — /EuropaWire/ — Hydra Biosciences, Inc., a leader in the field of transient receptor potential (TRP) channel modulation, and Boehringer Ingelheim today announced that they have entered into a worldwide research collaboration and license agreement to … Read the full press release
Posted in Business, Germany, Healthcare, Management, Pharma & Biotech, Science
Tagged Boehringer Ingelheim, Dr Reinhard Malin, Dr. Michel Pairet, Hydra Biosciences, research collaboration, Russell Herndon, small-molecule TRP inhibitors, transient receptor potential, treatment of renal diseases and disorders
For Non-US/Non-UK/Non-Canadian Media New analyses highlight undertreatment of high-risk AF patients1,2 First Phase II data demonstrating anticoagulant prescribing patterns in North America now available from GLORIA™-AF Registry Program Results presented at American College of Cardiology 64th Annual Scientific Session & … Read the full press release
• HOTLINE: New results from RE-LY® compare the effect of warfarin and Pradaxa® on kidney function in patients requiring anticoagulation • HOTLINE: GLORIA™-AF Registry Program benchmarks patient characteristics and antithrombotic use for stroke prevention in AF worldwide For Non-US/Non-UK/Non-Canadian Media … Read the full press release
For media outside of the US, the UK & Canada only The efficacy and safety profile of Pradaxa® (dabigatran etexilate) was maintained regardless of patient characteristics1,2,3,4 Pooled safety data favour Pradaxa® treatment over warfarin and provide further reassurance1-4 The analysed … Read the full press release
Ground-breaking ceremony for leading veterinary manufacturing plant in Taizhou/China Investment of 58 million Euro 200 job opportunities expected Taizhou, Jiangsu, China, and Ingelheim, Germany, 27-8-2013 — /EuropaWire/ — Today, the research driven pharmaceutical company Boehringer Ingelheim, in partnership with Taizhou China Medical … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged Animal Health, Boehringer Ingelheim, CHINA, China Animal Health markets, Dr Joachim Hasenmaier, Ingelheim, Jiangsu, Matthias Kagerbauer, Taizhou, Taizhou China Medical City, Taizhou China Medicine High-Tech Development Zone, veterinary vaccine manufacturing plant, veterinary vaccines, veterinary vaccines in Asia
Over 950 patients have now been successfully enrolled in the pivotal Phase III HCVerso™1 and 2 trials The Phase III study programme includes treatment naïve patients, including those ineligible for interferon and patients with liver cirrhosis The milestone coincides with … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged BI 207127, blood-borne infectious disease, Boehringer Ingelheim, Boehringer Ingelheim hepatitis C clinical trials, Dr Reinhard Malin, genoytpe-1 HCV, HCVerso™, HCVerso™ trials, hepatitis C clinical trials, hepatitis C virus, hronic liver disease, liver cancer, Phase IIb interferon-free SOUND-C2 study, Phase IIb SOUND-C3 study, pivotal Phase III HCVerso™1 and 2 trials, Professor Klaus Dugi, protease inhibitor faldaprevir, sustained virological response
For media outside of the US, the UK & Canada only Ingelheim, Germany, 26-8-2013 — /EuropaWire/ — Boehringer Ingelheim today announced the upcoming presentation of new data on the novel oral anticoagulant (NOAC) Pradaxa® (dabigatran etexilate) during the ESC Congress 2013 organised … Read the full press release
Posted in Germany, Healthcare, Pharma & Biotech, Science
Tagged atrial fibrillation, atrial fibrillation patient populations, Boehringer Ingelheim, dabigatran etexilate, ESC Congress 2013, ESC Congress 2013 in Amsterdam, European Society of Cardiology, Ingelheim, novel oral anticoagulant (NOAC) Pradaxa®, optimal stroke protection, pivotal RE-LY® trial, Pradaxa®, prevention of stroke and systemic embolism, Professor Klaus Dugi, Sara McClelland
2-7-2013 — /europawire.eu/ — New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions® (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with … Read the full press release
Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Science
Tagged 73rd Scientific Sessions®, American Diabetes Association, Boehringer Ingelheim, Diabetes, dipeptidyl peptidase-4, DPP-4, Dr. Odd Erik Johansen, Eli Lilly, Germany, Indianapolis, Ingelheim, Linagliptin, T2D, type 2 diabetes, US
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
